Add to ORKGCost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis The incremental cost effectiveness ratio (ICER) of cost/quality adjusted life year (QALY) for all available INF β Nikfar et al. DARU Journal of Pharmaceutical Sciences 2013, 21:5
Background/Aim. A cost-effectiveness analyses of immunomodulatory treatments for relapsing-remitting...
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis i...
As a chronic and disabling disease, multiple sclerosis (MS) is extremely costly, both for the indivi...
Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progr...
BACKGROUND: Multiple sclerosis (MS) is a highly debilitating immune mediated disorder and the second...
AbstractObjectiveThe objective of this study was to examine the cost-effectiveness of preventive tre...
Background:At the time of publication of the most recent National Institute for Health and Care Exce...
Background: At the time of publication of the most recent National Institute for Health and Care Exc...
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas...
Background: Interferon beta-1a (Avonex†) 30 mg, intramuscular (i.m.), once weekly is efficacious in ...
Introduction: The BENEFIT study has demonstrated the benefits of early treatment with interferon bet...
BACKGROUND: To differentiate five formulations of Interferon Beta for the treatment of multiple scle...
Background: Current first-line disease-modifying therapies (DMT) for multiple sclerosis (MS) patient...
BACKGROUND: In 2002, the UK's National Institute for Clinical Excellence (NICE) concluded that inter...
and IFN β-1a IM injection had the least favorable cost-effectiveness ratio ($141,721 per relapse avo...
Background/Aim. A cost-effectiveness analyses of immunomodulatory treatments for relapsing-remitting...
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis i...
As a chronic and disabling disease, multiple sclerosis (MS) is extremely costly, both for the indivi...
Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progr...
BACKGROUND: Multiple sclerosis (MS) is a highly debilitating immune mediated disorder and the second...
AbstractObjectiveThe objective of this study was to examine the cost-effectiveness of preventive tre...
Background:At the time of publication of the most recent National Institute for Health and Care Exce...
Background: At the time of publication of the most recent National Institute for Health and Care Exc...
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas...
Background: Interferon beta-1a (Avonex†) 30 mg, intramuscular (i.m.), once weekly is efficacious in ...
Introduction: The BENEFIT study has demonstrated the benefits of early treatment with interferon bet...
BACKGROUND: To differentiate five formulations of Interferon Beta for the treatment of multiple scle...
Background: Current first-line disease-modifying therapies (DMT) for multiple sclerosis (MS) patient...
BACKGROUND: In 2002, the UK's National Institute for Clinical Excellence (NICE) concluded that inter...
and IFN β-1a IM injection had the least favorable cost-effectiveness ratio ($141,721 per relapse avo...
Background/Aim. A cost-effectiveness analyses of immunomodulatory treatments for relapsing-remitting...
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis i...
As a chronic and disabling disease, multiple sclerosis (MS) is extremely costly, both for the indivi...